PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
PRODUCTS SOLD ON PEPTIDESLABIRELAND.COM ARE FOR RESEARCH PURPOSES ONLY AND ARE NOT FOR HUMAN OR VETERINARY USE.
Ipamorelin and CJC-1295 are two distinct research peptides that have been extensively studied in combination due to their complementary mechanisms of action on growth hormone (GH) secretion pathways. Both compounds act on the GH/IGF-1 axis — the hypothalamic-pituitary somatotropic system — but engage it through different receptor mechanisms, making their co-administration a frequent subject of combinatorial endocrinology research. Peptides Lab Ireland supplies both ipamorelin and CJC-1295 (with and without DAC) as research-grade lyophilised compounds for use exclusively by licensed researchers in approved Irish laboratory settings.
Ipamorelin is a synthetic pentapeptide with the molecular formula C₃₈H₄₉N₉O₅ and a molecular weight of 711.9 Da. It is classified as a growth hormone secretagogue (GHS) and a selective agonist of the ghrelin receptor (GHS-R1a) — the same receptor activated by the endogenous hormone ghrelin. By engaging GHS-R1a at the pituitary level, ipamorelin stimulates GH release without the pronounced stimulation of cortisol, prolactin, or ACTH that characterises older-generation GH secretagogues such as GHRP-6 and GHRP-2.
This selectivity is the defining characteristic of ipamorelin in the research context. Studies in rodent models have demonstrated that ipamorelin produces dose-dependent GH pulses that closely mimic the amplitude and duration of endogenous pulsatile GH release, without the supraphysiological hormonal spikes that complicate interpretation of results with less selective GHS compounds. Half-life in rodent models is approximately 2 hours without modification, making it suitable for acute pulse studies and controlled in vivo dosing paradigms.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), modified from the endogenous GHRH(1-29) sequence to enhance stability and extend plasma half-life. Two variants exist in the research literature:
CJC-1295 acts on the GHRH receptor (GHRHR) at the pituitary, stimulating GH synthesis and release. Unlike ipamorelin, which acts via ghrelin receptor engagement, CJC-1295 engages the GHRHR — a structurally and pharmacologically distinct pathway.
The scientific rationale for studying ipamorelin and CJC-1295 in combination derives from their synergistic receptor engagement. Ipamorelin (GHS-R1a agonism) and CJC-1295 (GHRHR agonism) act on distinct receptor populations at the anterior pituitary somatotroph cells, and their co-stimulation has been shown in preclinical models to produce greater GH pulse amplitude than either compound alone at equivalent individual doses — a synergistic rather than merely additive relationship.
Key research areas studied using the ipamorelin/CJC-1295 combination include:
Irish research institutions with programmes in endocrinology, geriatric biology, and sports science have particular relevance for GH axis research. Trinity College Dublin’s School of Medicine and the Royal College of Surgeons in Ireland both host active endocrine research programmes. Studies using ipamorelin and CJC-1295 in rodent or cell line models allow investigators to characterise GH/IGF-1 biology without the confounding effects of recombinant human GH, which introduces supraphysiological continuous stimulation incompatible with the study of endogenous pulsatile mechanisms.
Both compounds are unscheduled research substances in Ireland under the Misuse of Drugs Acts 1977–2016 and are not classified as licensed medicines by the HPRA. They are available exclusively for qualified researchers operating in licensed laboratory environments for in-vitro research purposes.
All batches supplied by Peptides Lab Ireland meet the following research-grade standards:
Ipamorelin is a ghrelin receptor agonist (GHS-R1a) that triggers GH release via the pituitary ghrelin pathway. CJC-1295 is a GHRH analogue that acts on the GHRH receptor (GHRHR). They engage different receptor populations but both ultimately stimulate pituitary GH secretion — making their combination a subject of synergy research.
DAC (Drug Affinity Complex) is a chemical modification that binds CJC-1295 to serum albumin, extending its half-life from approximately 30 minutes to 6–8 days. This creates a fundamentally different experimental model — sustained GH elevation rather than pulsatile release. Choosing between DAC and non-DAC versions is a critical experimental design decision, and Peptides Lab Ireland clearly identifies which variant each batch represents.
Neither compound is scheduled under the Misuse of Drugs Acts 1977–2016 or classified as a licensed medicine by the HPRA. Both may be purchased and held by qualified researchers for legitimate in-vitro laboratory research purposes. They are not for human or veterinary use.
These are research compounds supplied exclusively for in-vitro laboratory use. Peptides Lab Ireland makes no claims regarding human therapeutic application, and any use outside an approved research context is outside the scope of supply.
Preclinical research suggests the combination of ipamorelin and CJC-1295 produces greater GH pulse amplitude than either compound alone, due to dual-receptor engagement at the somatotroph. This synergistic effect is a primary reason the combination has attracted research interest as a model for studying the GH axis under enhanced secretagogue stimulation.
Legal Disclaimer: All compounds supplied by Peptides Lab Ireland are intended exclusively for in-vitro laboratory and scientific research purposes by licensed, qualified researchers. They are not medicines, not licensed therapeutic products, and not for human or veterinary administration. Peptides Lab Ireland does not provide medical advice, treatment recommendations, or dosage guidance for any human or clinical application. Use of any research compound must comply with all applicable Irish and EU legislation, including HPRA regulations and institutional ethics requirements.
Receive News
